INTS11 and cancer: The identification of Integrator, especially its catalytic subunit, INTS11, as a critical downstream component of this pathway opens the way to the development of small molecule inhibitors to Integrator, which may overcome the present therapeutic difficulties in targeting the MAPK pathway in cancer.